Dipna Pharmachem Ltd
Incorporated in 2011, Dipna Pharmachem Ltd
is in the business of Pharmaceutical Trading[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Commission Income Share of Total Revenue % ・Standalone data |
|
|||
| Number of Related Party Counterparties count ・Standalone data |
||||
| Related Party Purchases as % of Total Purchases % ・Standalone data |
||||
| Related Party Sales as % of Total Sales % ・Standalone data |
||||
| Trade Receivables Over 6 Months as % of Total % ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Outcome And Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
- Appointed Nirav Soni as additional director; noted two independent director resignations effective 10 August 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
- Dipna Pharmachem appointed Nirav Soni and noted resignations of two independent directors on 10 August 2026.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
- Dipna Pharmachem appoints Nirav Soni as director; Jitendra Parmar and Manish Bachani resign, effective 10 August 2026.
-
Board Meeting Outcome for Outcome And Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
- Board appointed Nirav Soni and noted resignations of Jitendra Parmar, Manish Bachani effective 10 August 2026.
-
Appointment of Company Secretary and Compliance Officer
- Board appointed Mr. Shyam Sundar Lohia as Company Secretary and Compliance Officer effective 5 August 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
Business Overview:[1]
DPL is a trader, importer, and exporter of industrial Chemical and Pharmaceutical Raw materials, APIs, Solvents, Excipients, Intermediates, and Formulations. It provides assistance in setting up contract manufacturing compliance for regulated, semi-regulated pharmaceutical companies with all the global benchmark parameters of certificates like WHO-GMP